Stocks · News reference
8-K filing — GRI Bio, Inc. (GRI)
Filed: 2026-09-08 AccNo: 0001824293-26-000057 Size: 4 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
GRI Bio Says Phase 2a GRI-0621 IPF Study Showed Placebo-Adjusted FVC Change Of +99 mL At Week 12, +139 mL On Background Antifibrotic Therapy; Says Data Supports Advancement Into Longer-Duration Study
GRI Bio shares are trading higher after the company announced three abstracts and an oral presentation highlighting data from the Phase 2a GRI-0621-IPF-02 study have been selected for presentation at ERS Congress 2026.